Keros Therapeutics Inc (KROS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Keros Therapeutics Inc (KROS) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.25 Million) by net assets ($703.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Keros Therapeutics Inc (KROS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Keros Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Keros Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Keros Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Tuna Environmental Science & Technology Co Ltd
SHG:603177
|
0.063x |
|
Guangzhou Seagull Kitchen And Bath Products Co Ltd
SHE:002084
|
0.042x |
|
Bredband2 i Skandinavien AB
ST:BRE2
|
0.127x |
|
Cadiz Inc
NASDAQ:CDZI
|
-0.298x |
|
Rejlers AB (publ)
ST:REJL-B
|
0.029x |
|
Plano & Plano Desenvolvimento Imobiliário S.A
SA:PLPL3
|
-0.118x |
|
Airsculpt Technologies Inc
NASDAQ:AIRS
|
0.053x |
|
BayCom Corp
NASDAQ:BCML
|
0.022x |
Annual Cash Flow Conversion Efficiency for Keros Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Keros Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Keros Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $571.55 Million | $-160.87 Million | -0.281x | +24.90% |
| 2023-12-31 | $332.21 Million | $-124.51 Million | -0.375x | -48.40% |
| 2022-12-31 | $277.42 Million | $-70.06 Million | -0.253x | +1.18% |
| 2021-12-31 | $243.17 Million | $-62.15 Million | -0.256x | -81.30% |
| 2020-12-31 | $261.72 Million | $-36.89 Million | -0.141x | +95.20% |
| 2019-12-31 | $5.45 Million | $-16.00 Million | -2.935x | -631.71% |
| 2018-12-31 | $12.76 Million | $7.04 Million | 0.552x | -- |
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias… Read more